Global pharmaceutical firms start prioritising patients over pricing
GSK puts drug affordability before IP protection in low-income countries.
A flexible approach towards pharmaceutical IP protection and adaptive pricing is making drugs more affordable and accessible in poorer countries, according to Vlerick business school.
Professor Walter Van Dyck and Professor Leo Neels discussed this following the recent decision of GSK, the London-based global healthcare pharmaceutical company, to not seek patent protection on medicines in low-income countries. The decision was made to broaden the access to pharmaceuticals for local authorities and patients.
Professor Neels says: “The new initiative is an elegant example of adaptive pricing… adapted that is, to the standard of living in different countries”.
The development will make GSK medicines freely available to manufacturers in low-income countries for local production, and presents a great example of how global companies can use a ‘non-market strategy’ to strive for stronger credibility and build trust with their consumers, according to Professor Van Dyck.
Middle-income countries will need license agreements arranged between GSK and manufacturers for a small fee, and full IP protection and consequential pricing will be applied in developed countries.
Van Dyck says: “While fundamentally market strategy is about making profits, a non-market strategy is about creating values, in this case about doing good.
“The ability for poorer countries to pay for pharmaceuticals is so low, so why not give it for – almost – free, but in a controlled way? In contrast to the developed world where they would take imitators to court. Overall, to do good for the poor? Or possibly to keep control of their brand and distribution in poor countries where they’d be copied otherwise anyway. They can also continue to fund innovation and by maintaining higher prices in the richer economies.”
Abid Kanji, a pharmaceutical expert and Associate Director at NonStop Recruitment, comments: “It’s highly encouraging to see a shift in the nature of the pharmaceutical sector which means that poorer countries around the world are likely to have improved access to potentially life-saving and changing drugs. This means firms as employers are likely to have to bolster their recruitment strategies to take on board more licensing and sales representatives to meet the increased demand. It’s going to be an interesting time for the entire industry, and many organisations will have to put increased focus on developing talent pipelines in regions they’re probably not as familiar with.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance